Endocrine side effects induced by immune checkpoint inhibitors

Salvatore Maria Corsello, Agnese Barnabei, Paolo Marchetti, Liana De Vecchis, Roberto Salvatori, Francesco Torino

Research output: Contribution to journalArticle

Abstract

Context: In recent years, progress has been made in cancer immunotherapy by the development of drugs acting as modulators of immune checkpoint proteins, such as the cytotoxic T-lymphocyte antigen-4(CTLA4) and programmed death-1 (PD-1), two co-inhibitory receptors thatareexpressed on T cells upon activation. These molecules play crucial roles in maintaining immune homeostasis by down-regulating T-cell signaling, thereby preventing unbridled T-cell proliferation while maintaining tolerance to self-antigens, such as tumor-associated antigens. CTLA4 blockade through systemic administration of the CTLA4-blocking antibody ipilimumab was shown to confer significant survival benefit and prolonged stable disease in patients affected by advanced cutaneous melanoma. Other immune checkpoint inhibitors are under clinical evaluation. However, immune checkpoint blockade can lead to the breaking of immune self-tolerance, thereby inducing a novel syndrome of autoimmune/autoinflammatory side effects, designatedas "immune-related adverse events," mainly including rash, colitis, hepatitis, and endocrinopathies. Data Acquisition: We searched the medical literature using the words "hypophysitis," "hypopituitarism," "thyroid," "adrenal insufficiency," and "endocrine adverse events" in association with "immune checkpoint inhibitors," "ipilimumab," "tremelimumab," "PD-1," and "PD-1-L." Evidence Synthesis: The spectrum of endocrine disease experienced by patients treated with ipilimumab includes most commonly hypophysitis, more rarely thyroid disease or abnormalities in thyroid function tests, and occasionally primary adrenal insufficiency. Hypophysitis has emerged as a distinctive side effect of CTLA4-blocking antibodies, establishing a new form of autoimmune pituitary disease. This condition, if not promptly recognized, may be life-threatening (due to secondary hypoadrenalism). Hypopituitarism caused by these agents is rarely reversible, and prolonged or lifelong substitutive hormonal treatment is often required. The precise mechanism of injury to the endocrine system triggered by these drugs is yet to be fully elucidated. Conclusions: Although reports of endocrine side effects caused by cancer immune therapy are abundant, their exact prevalence and mechanism are unclear. Well-designed correlative studies oriented to finding and validating predictive factors of autoimmune toxicity are urgently needed.

Original languageEnglish (US)
Pages (from-to)1361-1375
Number of pages15
JournalJournal of Clinical Endocrinology and Metabolism
Volume98
Issue number4
DOIs
StatePublished - Apr 2013

Fingerprint

CTLA-4 Antigen
T-cells
Adrenal Insufficiency
Hypopituitarism
Blocking Antibodies
T-Lymphocytes
Pituitary Diseases
Cell signaling
Endocrine System Diseases
Self Tolerance
Thyroid Function Tests
Addison Disease
Immune Tolerance
Endocrine System
Thyroid Diseases
Autoantigens
Cell proliferation
Neoplasm Antigens
Colitis
Exanthema

ASJC Scopus subject areas

  • Biochemistry
  • Clinical Biochemistry
  • Endocrinology
  • Biochemistry, medical
  • Endocrinology, Diabetes and Metabolism

Cite this

Endocrine side effects induced by immune checkpoint inhibitors. / Corsello, Salvatore Maria; Barnabei, Agnese; Marchetti, Paolo; De Vecchis, Liana; Salvatori, Roberto; Torino, Francesco.

In: Journal of Clinical Endocrinology and Metabolism, Vol. 98, No. 4, 04.2013, p. 1361-1375.

Research output: Contribution to journalArticle

Corsello, SM, Barnabei, A, Marchetti, P, De Vecchis, L, Salvatori, R & Torino, F 2013, 'Endocrine side effects induced by immune checkpoint inhibitors', Journal of Clinical Endocrinology and Metabolism, vol. 98, no. 4, pp. 1361-1375. https://doi.org/10.1210/jc.2012-4075
Corsello, Salvatore Maria ; Barnabei, Agnese ; Marchetti, Paolo ; De Vecchis, Liana ; Salvatori, Roberto ; Torino, Francesco. / Endocrine side effects induced by immune checkpoint inhibitors. In: Journal of Clinical Endocrinology and Metabolism. 2013 ; Vol. 98, No. 4. pp. 1361-1375.
@article{ec1d148476a1456ea6088fe536a6bcb5,
title = "Endocrine side effects induced by immune checkpoint inhibitors",
abstract = "Context: In recent years, progress has been made in cancer immunotherapy by the development of drugs acting as modulators of immune checkpoint proteins, such as the cytotoxic T-lymphocyte antigen-4(CTLA4) and programmed death-1 (PD-1), two co-inhibitory receptors thatareexpressed on T cells upon activation. These molecules play crucial roles in maintaining immune homeostasis by down-regulating T-cell signaling, thereby preventing unbridled T-cell proliferation while maintaining tolerance to self-antigens, such as tumor-associated antigens. CTLA4 blockade through systemic administration of the CTLA4-blocking antibody ipilimumab was shown to confer significant survival benefit and prolonged stable disease in patients affected by advanced cutaneous melanoma. Other immune checkpoint inhibitors are under clinical evaluation. However, immune checkpoint blockade can lead to the breaking of immune self-tolerance, thereby inducing a novel syndrome of autoimmune/autoinflammatory side effects, designatedas {"}immune-related adverse events,{"} mainly including rash, colitis, hepatitis, and endocrinopathies. Data Acquisition: We searched the medical literature using the words {"}hypophysitis,{"} {"}hypopituitarism,{"} {"}thyroid,{"} {"}adrenal insufficiency,{"} and {"}endocrine adverse events{"} in association with {"}immune checkpoint inhibitors,{"} {"}ipilimumab,{"} {"}tremelimumab,{"} {"}PD-1,{"} and {"}PD-1-L.{"} Evidence Synthesis: The spectrum of endocrine disease experienced by patients treated with ipilimumab includes most commonly hypophysitis, more rarely thyroid disease or abnormalities in thyroid function tests, and occasionally primary adrenal insufficiency. Hypophysitis has emerged as a distinctive side effect of CTLA4-blocking antibodies, establishing a new form of autoimmune pituitary disease. This condition, if not promptly recognized, may be life-threatening (due to secondary hypoadrenalism). Hypopituitarism caused by these agents is rarely reversible, and prolonged or lifelong substitutive hormonal treatment is often required. The precise mechanism of injury to the endocrine system triggered by these drugs is yet to be fully elucidated. Conclusions: Although reports of endocrine side effects caused by cancer immune therapy are abundant, their exact prevalence and mechanism are unclear. Well-designed correlative studies oriented to finding and validating predictive factors of autoimmune toxicity are urgently needed.",
author = "Corsello, {Salvatore Maria} and Agnese Barnabei and Paolo Marchetti and {De Vecchis}, Liana and Roberto Salvatori and Francesco Torino",
year = "2013",
month = "4",
doi = "10.1210/jc.2012-4075",
language = "English (US)",
volume = "98",
pages = "1361--1375",
journal = "Journal of Clinical Endocrinology and Metabolism",
issn = "0021-972X",
publisher = "The Endocrine Society",
number = "4",

}

TY - JOUR

T1 - Endocrine side effects induced by immune checkpoint inhibitors

AU - Corsello, Salvatore Maria

AU - Barnabei, Agnese

AU - Marchetti, Paolo

AU - De Vecchis, Liana

AU - Salvatori, Roberto

AU - Torino, Francesco

PY - 2013/4

Y1 - 2013/4

N2 - Context: In recent years, progress has been made in cancer immunotherapy by the development of drugs acting as modulators of immune checkpoint proteins, such as the cytotoxic T-lymphocyte antigen-4(CTLA4) and programmed death-1 (PD-1), two co-inhibitory receptors thatareexpressed on T cells upon activation. These molecules play crucial roles in maintaining immune homeostasis by down-regulating T-cell signaling, thereby preventing unbridled T-cell proliferation while maintaining tolerance to self-antigens, such as tumor-associated antigens. CTLA4 blockade through systemic administration of the CTLA4-blocking antibody ipilimumab was shown to confer significant survival benefit and prolonged stable disease in patients affected by advanced cutaneous melanoma. Other immune checkpoint inhibitors are under clinical evaluation. However, immune checkpoint blockade can lead to the breaking of immune self-tolerance, thereby inducing a novel syndrome of autoimmune/autoinflammatory side effects, designatedas "immune-related adverse events," mainly including rash, colitis, hepatitis, and endocrinopathies. Data Acquisition: We searched the medical literature using the words "hypophysitis," "hypopituitarism," "thyroid," "adrenal insufficiency," and "endocrine adverse events" in association with "immune checkpoint inhibitors," "ipilimumab," "tremelimumab," "PD-1," and "PD-1-L." Evidence Synthesis: The spectrum of endocrine disease experienced by patients treated with ipilimumab includes most commonly hypophysitis, more rarely thyroid disease or abnormalities in thyroid function tests, and occasionally primary adrenal insufficiency. Hypophysitis has emerged as a distinctive side effect of CTLA4-blocking antibodies, establishing a new form of autoimmune pituitary disease. This condition, if not promptly recognized, may be life-threatening (due to secondary hypoadrenalism). Hypopituitarism caused by these agents is rarely reversible, and prolonged or lifelong substitutive hormonal treatment is often required. The precise mechanism of injury to the endocrine system triggered by these drugs is yet to be fully elucidated. Conclusions: Although reports of endocrine side effects caused by cancer immune therapy are abundant, their exact prevalence and mechanism are unclear. Well-designed correlative studies oriented to finding and validating predictive factors of autoimmune toxicity are urgently needed.

AB - Context: In recent years, progress has been made in cancer immunotherapy by the development of drugs acting as modulators of immune checkpoint proteins, such as the cytotoxic T-lymphocyte antigen-4(CTLA4) and programmed death-1 (PD-1), two co-inhibitory receptors thatareexpressed on T cells upon activation. These molecules play crucial roles in maintaining immune homeostasis by down-regulating T-cell signaling, thereby preventing unbridled T-cell proliferation while maintaining tolerance to self-antigens, such as tumor-associated antigens. CTLA4 blockade through systemic administration of the CTLA4-blocking antibody ipilimumab was shown to confer significant survival benefit and prolonged stable disease in patients affected by advanced cutaneous melanoma. Other immune checkpoint inhibitors are under clinical evaluation. However, immune checkpoint blockade can lead to the breaking of immune self-tolerance, thereby inducing a novel syndrome of autoimmune/autoinflammatory side effects, designatedas "immune-related adverse events," mainly including rash, colitis, hepatitis, and endocrinopathies. Data Acquisition: We searched the medical literature using the words "hypophysitis," "hypopituitarism," "thyroid," "adrenal insufficiency," and "endocrine adverse events" in association with "immune checkpoint inhibitors," "ipilimumab," "tremelimumab," "PD-1," and "PD-1-L." Evidence Synthesis: The spectrum of endocrine disease experienced by patients treated with ipilimumab includes most commonly hypophysitis, more rarely thyroid disease or abnormalities in thyroid function tests, and occasionally primary adrenal insufficiency. Hypophysitis has emerged as a distinctive side effect of CTLA4-blocking antibodies, establishing a new form of autoimmune pituitary disease. This condition, if not promptly recognized, may be life-threatening (due to secondary hypoadrenalism). Hypopituitarism caused by these agents is rarely reversible, and prolonged or lifelong substitutive hormonal treatment is often required. The precise mechanism of injury to the endocrine system triggered by these drugs is yet to be fully elucidated. Conclusions: Although reports of endocrine side effects caused by cancer immune therapy are abundant, their exact prevalence and mechanism are unclear. Well-designed correlative studies oriented to finding and validating predictive factors of autoimmune toxicity are urgently needed.

UR - http://www.scopus.com/inward/record.url?scp=84876248304&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84876248304&partnerID=8YFLogxK

U2 - 10.1210/jc.2012-4075

DO - 10.1210/jc.2012-4075

M3 - Article

VL - 98

SP - 1361

EP - 1375

JO - Journal of Clinical Endocrinology and Metabolism

JF - Journal of Clinical Endocrinology and Metabolism

SN - 0021-972X

IS - 4

ER -